<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01629732</url>
  </required_header>
  <id_info>
    <org_study_id>AI472-007</org_study_id>
    <secondary_id>2012-002519-24</secondary_id>
    <nct_id>NCT01629732</nct_id>
  </id_info>
  <brief_title>Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C</brief_title>
  <official_title>Phase 2b Evaluation of PegIFNα Free Combinations of BMS-986094 (INX-08189) and Daclatasvir, With or Without Ribavirin, in Treatment Naive and Treatment Experienced Patients With Chronic Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of BMS-986094 and Daclatasvir
      (DCV) when given in combination with or without Ribavirin
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with SVR4 defined as HCV RNA &lt; LOQ (25 IU/mL; detectable or undetectable) at 4 weeks post treatment to be evaluated in GT1 (naive and NR) subjects randomized to the 12-week treatment arm (arms 1a, 2a, 3a, 4a)</measure>
    <time_frame>Follow up Week 4</time_frame>
    <description>SVR = Sustained virologic response
HCV = Hepatitis C virus
RNA = Ribonucleic acid
LOQ = Limit of quantitation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of treated subjects with SVR4 in genotype (GT) 1 naive and non-responder (NR) subjects randomized to the 24-week treatment arms (arms 1b, 2b, 3b, 4b)</measure>
    <time_frame>Follow up Week 4 (SVR4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of treated subjects with SVR4 in genotype 1 protease inhibitor (PI)failures, genotype 4 naive, and genotype 2/3 NR/relapse subjects (arms 5, 6, 7)</measure>
    <time_frame>Follow up Week 4 (SVR4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of treated subjects in each study population (GT1 naive, GT1 NR, or GT1 PI-failure, GT4 naive, GT2/3 NR/relapse), for each regimen and duration, who achieve HCV RNA &lt; LOQ at post-treatment</measure>
    <time_frame>Post-treatment Week 2 (SVR2), Week 8 (SVR8), Week 12 (SVR12), Week 24 (SVR24), and Week 36 (SVR36, for the 12 week arms)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of treated subjects in each study population, by regimen, who achieve HCV RNA &lt; LOQ (detectable/undetectable)</measure>
    <time_frame>Weeks 1, 2, 4, 6, 8, 12 and End of Treatment (Week 12 or 24)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects in each study population, be regimen, who achieve HCV RNA undetectable</measure>
    <time_frame>Weeks 1, 2, 4, 6, 8, 12 and End of Treatment (Week 12 or 24)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of BMS-986094 and DCV ± RBV as measured by the frequency of deaths, serious adverse events (SAEs), discontinuations due to Adverse Events (AEs), and severity Grade 3/4 laboratory abnormalities</measure>
    <time_frame>Up to post treatment Week 36</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>Arm 1: Daclasasvir + BMS-986094 (100 mg) + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)
Re-Randomized Arm 1 to Arm 1a and 1b (additional 12 weeks treatment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Daclasasvir + BMS-986094 (200 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)
Re-Randomized Arm 2 to Arm 2a and 2b (additional 12 weeks treatment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Daclasasvir + BMS-986094 (100 mg) + Placebo + Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)
Re-Randomized Arm 3 to Arm 3a and 3b (additional 12 weeks treatment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: Daclasasvir + BMS-986094 (200 mg) + Ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be re-randomized at Week 12 to complete therapy at this visit and enter post-treatment follow-up, or continue therapy for an additional 12 weeks (24 weeks of therapy)
Re-Randomized Arm 4 to Arm 4a and 4b (additional 12 weeks treatment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5: Daclasasvir + BMS-986094 (200 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genotype 1 PI-failure subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6: Daclasasvir + BMS-986094 (200 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genotype 4 naive subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 7: Daclasasvir + BMS-986094 (200 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Genotype 2/3 NR/relapse Subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <description>Film coated tablet, Oral, 60 mg, Once daily, 12 or 24 weeks</description>
    <arm_group_label>Arm 1: Daclasasvir + BMS-986094 (100 mg) + Placebo</arm_group_label>
    <arm_group_label>Arm 2: Daclasasvir + BMS-986094 (200 mg)</arm_group_label>
    <arm_group_label>Arm 3: Daclasasvir + BMS-986094 (100 mg) + Placebo + Ribavirin</arm_group_label>
    <arm_group_label>Arm 4: Daclasasvir + BMS-986094 (200 mg) + Ribavirin</arm_group_label>
    <other_name>BMS-790052 (DCV)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclatasvir</intervention_name>
    <description>Film coated tablet, Oral, 60 mg, Once daily, 24 weeks</description>
    <arm_group_label>Arm 5: Daclasasvir + BMS-986094 (200 mg)</arm_group_label>
    <arm_group_label>Arm 6: Daclasasvir + BMS-986094 (200 mg)</arm_group_label>
    <arm_group_label>Arm 7: Daclasasvir + BMS-986094 (200 mg)</arm_group_label>
    <other_name>BMS-790052 (DCV)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986094</intervention_name>
    <description>Capsule, Oral, 100 mg, Once daily, 12 or 24 weeks</description>
    <arm_group_label>Arm 1: Daclasasvir + BMS-986094 (100 mg) + Placebo</arm_group_label>
    <arm_group_label>Arm 3: Daclasasvir + BMS-986094 (100 mg) + Placebo + Ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986094</intervention_name>
    <description>Capsule, Oral, 200 mg, Once daily, 12 or 24 weeks</description>
    <arm_group_label>Arm 2: Daclasasvir + BMS-986094 (200 mg)</arm_group_label>
    <arm_group_label>Arm 4: Daclasasvir + BMS-986094 (200 mg) + Ribavirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986094</intervention_name>
    <description>Capsule, Oral, 200 mg, Once daily, 24 Weeks</description>
    <arm_group_label>Arm 5: Daclasasvir + BMS-986094 (200 mg)</arm_group_label>
    <arm_group_label>Arm 6: Daclasasvir + BMS-986094 (200 mg)</arm_group_label>
    <arm_group_label>Arm 7: Daclasasvir + BMS-986094 (200 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Film coated tablet, Oral, 1000 mg or 1200 mg based on weight, Twice daily, 12 or 24 weeks</description>
    <arm_group_label>Arm 3: Daclasasvir + BMS-986094 (100 mg) + Placebo + Ribavirin</arm_group_label>
    <arm_group_label>Arm 4: Daclasasvir + BMS-986094 (200 mg) + Ribavirin</arm_group_label>
    <other_name>Copegus®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for BMS-986094</intervention_name>
    <description>Capsule, Oral, 0 mg, Once daily, 12 or 24 weeks</description>
    <arm_group_label>Arm 1: Daclasasvir + BMS-986094 (100 mg) + Placebo</arm_group_label>
    <arm_group_label>Arm 3: Daclasasvir + BMS-986094 (100 mg) + Placebo + Ribavirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females, ≥ 18 years of age

          -  Subjects chronically infected with Hepatitis C virus (HCV) genotype 1,2,3 or 4

          -  HCV RNA viral load ≥ 10,000 IU/mL

          -  Subjects with compensated cirrhosis are permitted (compensated cirrhotics are capped
             at approximately 25% of treated population)

          -  Body Mass Index (BMI) of 18 to 35 kg/m2

          -  Seronegative for Hepatitis C virus (HIV) and Hepatitis B

        Exclusion Criteria:

          -  Evidence of decompensated liver disease

          -  Evidence of medical condition contributing to chronic liver disease other than HCV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2012</study_first_submitted>
  <study_first_submitted_qc>June 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2012</study_first_posted>
  <last_update_submitted>May 8, 2014</last_update_submitted>
  <last_update_submitted_qc>May 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

